Cardiodynamic trial of Piclidenoson (CF101) in healthy volunteer

Trial Profile

Cardiodynamic trial of Piclidenoson (CF101) in healthy volunteer

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Glaucoma; Osteoarthritis; Plaque psoriasis; Rheumatoid arthritis; Uveitis
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Aug 2017 New trial record
    • 07 Aug 2017 According to a Can-Fite BioPharma media release, in this study, piclidenoson doses were up to 3-fold higher than the highest dose expected to be used in the registration-directed clinical trials
    • 07 Aug 2017 According to a Can-Fite BioPharma media release, this trial is a regulatory safety requirement of both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) prior to the initiation of Phase III studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top